OSAKA, Japan, March 4, 2024 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that we have commenced the second phase of our collaboration with Nagasaki University (Location: Nagasaki, Nagasaki Prefecture; President: Takeshi Nagayasu), with a focus on comprehensive cooperation in the field of infectious diseases, particularly malaria.
In February 2019, we signed an agreement (hereinafter referred to as "the Agreement") with Nagasaki University to facilitate this cooperation. We have been working diligently on the activities outlined in the Agreement and have now decided to proceed with the second phase.
During the first phase (February 2019 to March 2024), Shionogi and Nagasaki University collaborated closely with seven newly partnered institutions※ and made significant progress in research related to the prevention and treatment of malaria. We also established a foundation for drug discovery research in malaria. In drug discovery, we discovered new candidate compounds and established highly effective vaccine modalities for vaccine research. In the second phase (April 2024 to March 2029), building upon the achievements of the first phase, we will expedite the transition of candidate compounds to early development stages and continue to explore new drug discovery research to address unmet needs.
※Kitasato Institute, National Institute of Infectious Diseases, GHIT Fund, Medicines for Malaria Venture(MMV), Osaka Metropolitan University, Mount Kenya University, Ehime University
For Further Information, Contact:
SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html
References